Cargando…
Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide
SIMPLE SUMMARY: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among women globally. Due to its biological heterogeneity, breast cancer treatment and prognosis are highly variable among patients. In particular, the triple-negative subtype (TNBC) has...
Autores principales: | Jannoo, Riaz, Walker, William, Kanamarlapudi, Venkateswarlu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216279/ https://www.ncbi.nlm.nih.gov/pubmed/37345109 http://dx.doi.org/10.3390/cancers15102772 |
Ejemplares similares
-
Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
por: Jannoo, Riaz, et al.
Publicado: (2023) -
The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression
por: Thompson, Aiysha, et al.
Publicado: (2014) -
Recent advances in understanding the role of glucagon-like peptide 1
por: Reed, Josh, et al.
Publicado: (2020) -
Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
por: Thompson, Aiysha, et al.
Publicado: (2016) -
Cytolytic Heterogeneity of Polymorphonuclear Leukocytes in Killing of Murine Tumor Cells
por: Yamazaki, Masatoshi, et al.
Publicado: (1988)